Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-07
2011-06-07
Kim, Jennifer M (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07956065
ABSTRACT:
This application describes method of treating dementia and cognitive deficits associated with dementia that involve administration of dihydrotetrabenazine, and isomers and/or pharmaceutically acceptable salts thereof.
REFERENCES:
patent: 2830993 (1958-04-01), Brossi et al.
patent: 2843591 (1958-07-01), Brossi et al.
patent: 2954382 (1960-09-01), Osbond
patent: 3009918 (1961-11-01), Openshaw et al.
patent: 3045021 (1962-07-01), Brossi
patent: 3053845 (1962-09-01), Tretter
patent: 3079395 (1963-02-01), Brossi et al.
patent: 3095419 (1963-06-01), Tretter
patent: 3105079 (1963-09-01), Tretter
patent: 3123609 (1964-03-01), Openshaw et al.
patent: 3132147 (1964-05-01), Schopf et al.
patent: 3159638 (1964-12-01), Ritchie et al.
patent: 3209005 (1965-09-01), Brossi et al.
patent: 3314966 (1967-04-01), Brossi et al.
patent: 3342825 (1967-09-01), Openshaw et al.
patent: 3375254 (1968-03-01), Openshaw et al.
patent: 3390152 (1968-06-01), Harnden
patent: 3634431 (1972-01-01), Van Dyke
patent: 3635986 (1972-01-01), Van Dyke
patent: 4076820 (1978-02-01), Archibald et al.
patent: 4102886 (1978-07-01), Szantay et al.
patent: 4133812 (1979-01-01), Szaantay et al.
patent: 4304913 (1981-12-01), Havera et al.
patent: 4353656 (1982-10-01), Sohl et al.
patent: 4778054 (1988-10-01), Newell et al.
patent: 4811731 (1989-03-01), Newell et al.
patent: 5035237 (1991-07-01), Newell et al.
patent: 5590645 (1997-01-01), Davies et al.
patent: 5860419 (1999-01-01), Davies et al.
patent: 5873360 (1999-02-01), Davies et al.
patent: 6087376 (2000-07-01), Crooks et al.
patent: 6462069 (2002-10-01), Reich et al.
patent: 6482986 (2002-11-01), Boigegrain et al.
patent: 6632666 (2003-10-01), Baust et al.
patent: 2005/0064034 (2005-03-01), Li et al.
patent: 2006/0173011 (2006-08-01), Shin et al.
patent: 2008/0108645 (2008-05-01), Tridgett et al.
patent: 2008/0319000 (2008-12-01), Tridgett
patent: 2009/0275605 (2009-11-01), Duffield et al.
patent: 2010/0055133 (2010-03-01), Duffield et al.
patent: 2010/0063086 (2010-03-01), Nichols
patent: 2010/0087475 (2010-04-01), Duffield et al.
patent: 2010/0087476 (2010-04-01), Duffield et al.
patent: 2011/0053866 (2011-03-01), Duffield et al.
patent: 0069715 (1983-01-01), None
patent: 0839805 (1998-06-01), None
patent: 2064336 (1981-06-01), None
patent: 2129691 (1984-05-01), None
patent: 2169265 (1986-07-01), None
patent: 2178965 (1987-02-01), None
patent: 2242134 (1991-09-01), None
patent: 2410947 (2005-08-01), None
patent: 2463452 (2010-03-01), None
patent: WO-2005077946 (2005-08-01), None
patent: WO-2006069030 (2006-06-01), None
patent: WO-2007007105 (2007-01-01), None
patent: WO-2007017643 (2007-02-01), None
patent: WO-2007017654 (2007-02-01), None
patent: WO-2008079404 (2008-07-01), None
patent: WO2009150474 (2009-12-01), None
patent: WO2011019956 (2011-02-01), None
“U.S. Appl. No. 10/597,803, Final Office Action mailed Oct. 27, 2009”, 22 Pgs.
“U.S. Appl. No. 10/597,803, Response filed Jul. 29, 2009 to Non Final Office Action mailed Jan. 29, 2009”, 26 pgs.
“European Application Serial No. 05708289.3, Response filed Sep. 17, 2007”, 8 pgs.
“International Application Serial No. PCT/GB2005/000464, International Search Report mailed Jun. 10, 2005”, 4 pgs.
“International Application Serial No. PCT/GB2005/000464, Preliminary Report on Patentability mailed Aug. 14, 2006”, 9 pgs.
“International Application Serial No. PCT/GB2005/000464, Written Opinion mailed Jun. 10, 2005”, 8 pgs.
“SYNKEM European DMF for Tetrabenazine”, (Sep. 2005), 145 pgs.
Albin, R. L, et al., “Increased ventral striatal monoaminergic innervation in Tourette syndrome”, Neurology, 61(3), (Aug. 12, 2003), 310-5.
Aranda, G., et al., “Synthesis and biological activity of iodinated and photosensitive derivatives of tetrabenazine”, European Journal of Medicinal Chemistry, 25(4), (May 1990), 369-374.
Balkissoon, Ronald, “Asthma Overview”, Primary Care: Clinics in Office Practice, vol. 35, Iss 1, (Mar. 2008), 41-60.
Berge, Stephen M, et al., “Pharmaceutical Salts”, J. Pharm Sci., 66(1), (1977), 1-19.
Bohnen, N. I, et al., “Decreased striatal monoaminergic terminals in Huntington disease”, Neurology, 54(9), (May 9, 2000), 1753-9.
Brossi, et al., “Syntheseversuche in der Emetin-Reihe 3. Mitteilung: 2-Hydroxy-hydrobenzo[a]chinolizine”, Helvetica Chimica Acta vol. XLI, No. 193, (1958), 1793-1806.
Brossi, et al., “Syntheseversuche in der Emetin-Reihe 4. Mitteilung: Racemisches 2-Dehydro-emetin”, Helvetica Chimica Acta vol. 42, (1959), 772-788.
Brossi, et al., “Syntheseversuche in der Emetin-Reihe 7. Mitteilung: Abbau und Synthese substituierter 2-Oxo-hydrobenzo[a]chinolizine”, Helvetica Chimica Acta, vol. XLIII, No. 77, (1960), 583-593.
Brossi, et al., “Syntheseversuche in der Emetinreihe 9. Mitteilung: Die Absolute Konfiguration von (-)-2-Dehydro-emetin”, Helvetica Chimica Acta, vol. XLV No. 257, (1962), 2219-2226.
Brossi, et al., “Synthetic Experiments in the Emetine Series”, Helv. Chim. Acta. vol. XLI, No. 193, (1958), 119-139.
Brossi, A., et al., “Synthese und absolute Konfiguration von (-)-2-Dehydroemetin”, Experentia, (1962), 211-212.
Brossi, A., et al., “Syntheseversuche in der Emetin-Reihe 2. Mitteilung: Neue Reaktionen mit 3,4-dihydro-isochinolinen”, Chimia, 12, (1958), 114-115.
Brossi, A., et al., “Syntheseversuche in der Emetinreihe 8. Mitteilung Rac. Emetin-Isomere der 2,3-cis-Reihe”, Helvetica Chimica Acta, 45(6), (1962), 1899-1907.
Brossi, V. A, et al., “Synthesen in der Emetin-Reihe”, Arzneimittel Forschung, 15, (1965), 670-674.
Bruderer, et al., “Synthesen in der Emetin-Reihe 11. Mitteliung: 2-Aryisubstituierte Hydrobenzo[a]chinolizine”, Helvetica Chimica Acta, 47(203), (1964), 1852-1860.
Canney, et al., “Amino- and Amido-Tetrabenazine Derivatives: Synthesis and Evaluation as Potential Ligands for the Vesicular Monoamine Transporter”, Nucl. Med. Biol. 22, (1995), 527-535.
Dasilva, et al., “Characterization of [11C]Tetrabenazine as an in Vivo Radioligand for the Vesicular Monoamine Transporter”, Nucl. Med. Biol vol. 21, No. 2, (1994), 151-156.
Dasilva, et al., “In Vivo Binding of [11C]Tetrabenazine to Vesicular Monoamine Transporters in Mouse Brain”, Life Sciences vol. 51, (1992), 593-600.
Dasilva, et al., “In Vivo Imagine of Monoaminergic Nerve Terminals in Mormal and MPTP-Lesioned Primate Brain Using Positron Emission Tomography (PET) and [11C]Tetrabenazine”, Synapse 14, (1993), 128-131.
Dasilva, J. N, et al., “Synthesis of a [11C]methoxy derivative of alpha-dihydrotetrabenazine: a radioligand for studying the vesicular monoamine transporter.”, Appl Radiat Isot., 44(12), (Dec. 1993), 1487-9.
De Silva, Jean, et al., “Synthesis of [11C]Tetrabenazine, a Vesicular Monoamine Uptake Inhibitor, for PET Imaging Studies”, Appl. Radiat. Isot. vol. 44: No. 4, (1993), 673-676.
Flack, et al., “Reporting and evaluating absolute-structure and absolute-configuration determinations”, Journal of Applied Crystallography 33, (2000), 1143-1148.
Frey, et al., “Imagine of Monoaminergic and Cholinergic Vesicular Transporters in the Brain”, Advances in Pharmacology vol. 42, (1998), 269-272.
Frey, et al., “Presynaptic Monoaminergic Vesicles in Parkinsons Disease and Normal Aging”, Ann. Neurol. 40, (1996), 873-884.
Gerecke, M, et al., “Syntheseversuche in der Emetin-Reihe 10. Mitteilung: Zur Oxydation von 2-Dehydro-emetin-Verbindungen mit Quecksilber(II)-acetat”, Helvetica Chimica Acta, vol. 47 No. 121, (1964), 1117-1123.
Gilman, et al., “Decreased Striatal Monoaminergic Terminals in Olivopontocerebellar Atrophy and Multiple System Atrophy Demonstrated with Positron Emission Tomography”, Ann. Neurol 40, (1996), 885-892.
Jankovic, J., et al., “Long-term effects of tetrabenazin
Biovail Laboratories International (Barbados) S.R.L.
Kim Jennifer M
Schwegman Lundberg & Woessner, P.A.
LandOfFree
Pharmaceutical compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2672938